Optimapharm announces Sara Weytjens as Vice President, Regulatory and Site Activation

Optimapharm, a leading, mid-sized, full-service CRO across Europe and North America, is excited to announce the appointment of Sara Weytjens as Vice President, Regulatory and Site Activation, effective April 2023

Sara Weytjens has joined Optimapharm bringing extensive experience in clinical operations, regulatory affairs, and project management. Her professional career in clinical operations started in 1999 as CRA for both CRO and Pharma prior to joining Pharm-Olam CRO in 2004 to continue her professional development as Lead CRA, Project Manager, Clinical Operations Manager and Country Manager during several years. From 2016, Sara was leading Regulatory Affairs and developed significant expertise in transforming the Regulatory Affairs department into a Global Site Activation Unit covering regulatory, start-up management, site contract and budget, and green light package approval processes.

From January 2022, Sara worked to prepare her company for new CTR having experience getting approvals in CTIS.

Sara holds an MSc in Biochemistry from the University of Leuven, Belgium, and is a Board Member of BeCRO.

"Throughout my career, I have been blessed with many opportunities on my path and to learn from stimulating & enlightening managers along that journey. I'm looking forward to the exciting challenge of evolving the Regulatory and Start-Up department at Optimapharm, supporting my team, our organization and serving our clients" said Sara Weytjens, Vice President, Regulatory and Site Activation. To quote Robert Collier, *"Success is the sum of small efforts, repeated day-in and day-out."*

About Optimapharm

Optimapharm is a leading, mid-sized, full-service CRO across Europe and North America focused on our People, consistent quality delivery to our Clients, and supporting the development of new therapies to improve and save Patients' lives. The company provides successful tailor-made clinical research solutions to Biotech, Pharma, and Medical Device companies in 41 countries.

With 27 strategically located offices, Optimapharm is giving unrivaled access to Patients and Investigators in all countries in Europe and North America, with a total population of over 900 million people. Optimapharm conducts phase I – IV studies in all therapeutic areas, specifically focusing on Oncology/Haemato-oncology, Cardio-metabolic, CNS, Respiratory, GI&GU, Immunology/Rheumatology, and in complex medical device studies. With very strong operational teams, Optimapharm has a reputation for excellence delivery in all projects, including rescue studies.

Optimapharm - We Deliver on Your Promises. Web site: https://optimapharm.eu/